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SUMMARY 
Complete tumour regression is the optimal outcome of cancer therapies. There are however 
types of tumours that naturally regress. Most of these are benign, dermatological and have an 
early onset in life. This literature study aims to elucidate the mechanisms behind spontaneous 
tumour regression. In Libechov Melanoblastoma-Bearing minipigs, an animal-model 
specifically bred to develop malignant melanoma, the tumours usually involute within three 
months. This has been proven to be the effect of a lymphocytic infiltrate, predominated by 
cytotoxic T-cells. An epidermotropic myeloid tumour of Langerhans cell origin, frequently 
seen in young dogs, is called histiocytoma and is known to have a very brief proliferation 
followed by a quick remission. The involuting process is due to extensive lymphoid infiltrate. 
In hemangioma, rapid growth of the tumour is followed by a regressing stage that has been 
linked to apoptosis, possibly induced by mast cells. As in the case of hemangioma, infantile 
mastocytomas are known to regress before the child reaches puberty. The series of events 
behind the remission remains poorly investigated, but is thought to be connected to increased 
apoptosis of tumour cells. Another self-involuting tumour of the skin is the virus-induced 
papilloma, which self-keratinizes to oblivion. The infected cells become terminally 
differentiated and thus lose their ability of mitosis. There appears to be no overall explanation 
as to why and how spontaneous tumour regression occurs, but different types of tumours seem 
be unique from one another. 
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SAMMANFATTNING 
Målet med cancerbehandling är en total tillbakagång av den maligna tumören. Det finns dock 
dokumenterade cancerfall där hela tumören gått i regress utan att behandling satts in. På den 
benigna sidan finns tumörtyper där spontan tumörregression är ett välkänt faktum. 
Gemensamt för de flesta av dessa är att de är lokaliserade till huden samt att de ofta bildas 
tidigt i livet. Denna litteraturstudie syftar till att utreda bakomliggande mekanismer till 
spontan tumörregression. Melanoblastom-bärande Libechov-minigrisar är en 
försöksdjursmodell speciellt framtagen för att studera patogenes och regression av malignt 
melanom. Djuren utvecklar maligna tumörer inom tre månader post partus, vilka sedan går i 
regress inom kort. Man har i studier visat att detta beror på att tumörcellerna stöts bort av 
grisarnas immunförsvar. En liknande mekanism har påvisats i kutant histiocytom, vilket ofta 
drabbar unga hundar. I båda fallen drivs tumörregressionen av ett T-cellsdominerat 
immunsvar huvudsakligen bestående av cytotoxiska T-celler. Infantilt hemangiom är en annan 
tumör som går tillbaka spontant. I studier har detta visats bero på en ökad apoptos av 
tumörcellerna och en del resultat indikerar att mastceller är den inducerande faktorn. Precis 
som i hemangiom tros apoptos vara en förklaring till att infantila mastocytom går i regress. 
Terminal differentiering är den bakomliggande orsaken till varför virus-inducerade papillom 
så småningom tillbakabildas. När cellerna blir slutgiltigt differentierade förlorar de sin 
förmåga att dela sig och blir tillslut keratiniserade och dör. Det verkar inte gå att hitta en 
generell förklaring till varför en del tumörer går i spontan regression. De fall som finns 
skildrade i litteraturen uppvisar vitt skilda mekanismer. 
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INTRODUCTION 
The development of tumours in mammals is seen frequently and is closely related to ageing.  
The more times a cell undergoes mitosis, the higher the risk of mutation occurring in the 
DNA.  However, tumour development is not completely isolated to maturing populations, but 
can appear at any age. Furthermore, neoplasms could be divided into two categories: 
malignant and benign. The malignant tumour, usually referred to as cancer, is one of the 
leading causes of death in the world (Elston, 2004). 
 
However, sometimes tumours undergo natural remission without being treated. Mostly these 
tumours are benign, but there are known cases in which cancers (malignant tumours) have 
regressed and the patients have fully recovered (Elston, 2004). 
 
This literature study aims to answer the question of which mechanisms are responsible for 
spontaneous tumour regression; is there a general series of events or are all cases unique from 
one another? The tumour types examined in this study all exemplify natural involution and 
thus, were chosen to give a deeper insight into the subject. 
 
Understanding the mechanisms behind self-generated involution of tumours could help to 
predict tumour behaviour, to comprehend the development of tumours and most important of 
all, could be used in the development of more effective cancer therapies. 
 
 
MATERIAL AND METHODS 
Since tumour research is a very progressive field in the world of science, the number of 
articles published is too numerous to count. Therefore it is usually wisest to carefully limit 
search criteria to facilitate the process of finding relevant information. In time, it became clear 
that the field regarding spontaneous regression of tumours remains relatively unexplored and 
there is not much written on the specific subject. In particular on the veterinary side, adequate 
data was missing; subsequently this essay contains facts taken from both human and animal 
studies. 
 
The references used were found through databases such as PubMed, Google Scholar and Web 
of Science. The main keywords used in different combinations were “spontaneous, self-
generated, tumor/tumour, tumors/tumours, regression, involution, remission, mechanism, 
mechanisms, mastocytoma, mast cell tumor, cutaneous, hemangioma, histiocytoma, HPV, 
melanoma”. 
 
Delving into research obtained from some articles directly led on to other work that had been 
done in similar fields. To be able to present a sufficient background to some of the parts in the 
essay, review-articles were used. 
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LITERATURE REVIEW 
Melanoma 
Melanoblastoma-bearing Libechov minipigs 
To closer study the pathology, tumour progression and tumour regression of melanoma, 
several animal-models have been developed for this specific purpose. A frequently used 
animal-model is the melanoblastoma-bearing Libechov minipig (MeLiM swine model).  The 
breed is exposed to a very high incidence (50%) of malignant melanoma and piglets usually 
develop tumours within three months after birth. The tumours share fundamental 
characteristics with human malignant melanomas and can be classified according to the same 
system to a large extent. Clinically, the melanomas appear flat to exophytic and of varying 
size and varying intensity of pigmentation. Occasionally, ulceration of the lesion is seen.  It is 
not uncommon that different types of melanomas can be found in the same animal. 
Histologically, melanin-filled keratinocytes are abundant along atypical melanocytes. There 
are very few lymphatic cells infiltrating the tumour. The neoplasms commonly display a 
highly invasive growth and on post-mortem examination, extensive metastasising is usually 
shown, especially in rapid growing tumours (Vincent-Naulleau et al., 2004). 
 
Genetic signature in tumour regression 
Approximately three months after developing melanoma, regression of the tumour is seen in 
the MeLiM minipig. Since the tumour onset occurs at a very early stage in the life of the 
animals, both proliferation and regression of the tumour occurs in a continuum, making it 
difficult to distinguish distinct phases of the process. However, remission of the primary 
tumour is generally characterised by a drying of the tumour, followed by keratosis and a 
reduction in size. The pigmentation of the melanoma fades and the lesion becomes grey. A 
flattening and softening of the surface is common, finally leaving a scar or no visible trace of 
the tumour. On a microscopic level, dense infiltrates of lymphocytes are seen in the tissue 
with a foci consisting of fibrous tissue. There is also a high abundance of heavily pigmented 
histiocytes. Regression of the tumour is usually accompanied with depigmentation of hair, iris 
and skin. The loss of pigment is sometimes localized to a halo around the regressing lesion, 
but can include the whole body (Vincent-Naulleau et al., 2004). 
 
In 2008, Rambow et al. (2008) performed a study on tissue samples and cell cultures collected 
from MeLiM melanomas to explore if a significant alteration in the gene expression 
throughout the course of proliferation and regression in the tumour could be discovered. The 
results were obtained using suppression subtractive hybridization (SSH). Based on this study's 
results, 1411 genes were found to have an altered expression during the period looked at and 
these were further classified into different groups depending on their functions. The gene 
groups were as follows: cell death, cell cycle, cellular movement, immune response, hair and 
skin development and function, DNA-replication, DNA-recombination and DNA-repair. At an 
early stage in the regression, a number of genes belonging to the groups cell cycle, DNA-
replication, DNA-repair and DNA-recombination were significantly down-regulated. Most of 
these genes were connected to the cell cycle and DNA-repair-groups, coding for cyclins, 
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cyclin dependant kinases and spindle and chromosome related proteins. 70 % of the genes 
were directly related to mitosis. This suggests that the cell cycle and proliferation of the 
tumour cells are arrested shortly into the process of involution. Furthermore, up-regulation of 
macrophage/monocyte related genes were detected, explaining the elevated numbers of 
histiocytes seen in the tumour. This was interpreted as the first attempt of the immune system 
to eliminate highly immunogenic cancer cells. Later in the remissive state, a number of 
immune-system related genes were noticeably up-regulated, coding for T-cell receptors 
(TCRs), T-cell cytokines, effector molecules such as perforin and granzyme B, and 
immunoglobulins such as IGHM (IgM chain C region). Flow cytometry was used to 
determine the origin of the tumour infiltrating lymphocytes (TILs) which appeared to consist 
mainly of CD8
+
 T-cells (CTLs).  At a very late stage in the regression of the tumour, the 
MLANA-gene, coding for a melanosomal protein, was markedly down-regulated, along with 
the down-regulation of genes involved in the melanogenesis (ex. SILU, SLC24A5, OCA2, 
CITED1, TYR). This could explain the major decrease in melanoma cells. Finally a large 
number of apoptopic genes (for instance CLU, ELMO1, PLEKHF1, THY1) was higher 
expressed in the late stages of the regression along with a higher expression of ubiquitin D 
(which serves as a marker for proteins ready for destruction) and clusterin (an apoptosis-
related protein).  To sum up the results, the malignant melanoma seen in MeLiM-minipigs 
undergoes spontaneous involution. At an early stage of regression, the cell cycle is halted and 
histiocytes are recruited to the tumour site. Later on, the tumour is infiltrated by T-
lymphocytes, mainly CTLs and expression of genes with immune-response promoting 
functions are up-regulated which consequently leads to increased apoptosis and complete 
involution of the melanoma. What initially triggers this involution remains undiscovered 
(Rambow et al., 2008). 
 
Mastocytoma 
Pathology of mastocytoma 
Aggregates of mast cells are called mastocytomas and are usually the clinical manifestation of 
pathologically increased blood levels of mast cells, a condition named mastocytosis (Valent et 
al., 2001). The pathogenesis still remains relatively unknown although recent studies hint that 
mutations in the protooncogene, c-KIT (sometimes called stem cell factor, SCF), that codes 
for the receptor for mast cell growth factor may play a part in the development of 
mastocytosis (Longley et al., 1996).  Mastocytomas usually appear as skin lesions, moreover, 
other internal organs might be involved, especially in adults (Valent et al., 2001). Cutaneous 
mastocytomas can be further classified into different subgroups. The urticaria pigmentosa is 
the most common form and shows as red-brown regular-shaped macules or papules. In 
infants, cutaneous lesions normally present as solitary or multiple mastocytomas. These are 
known to undergo involution within a few years. Less frequently seen are the diffuse 
cutaneous mastocytosis, the erythrodermic diffuse cutaneous mastocytosis and telangiectasia 
macularis eruptive persistans (Hartmann & Henz 2001). 
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Regression of infantile mastocytomas 
In infants, the remission of cutaneous lesions is a common occurrence. In most cases the 
tumour first appears within a couple of months after birth. A proliferative phase (PS) is 
followed by a regression stage (RS) and the lesion will normally vanish before the child 
reaches puberty (Hartmann et al., 2003). 
 
A comparative study between the two phases showed that during PS the mast cells expressed 
proliferative cell nuclear antigen (PCNA). Dense infiltrates of mast cells in the dermis were 
seen histologically together with drawn out epidermal ridges. In RS no PCNA-expressing 
cells were found, indicating that the proliferation had ceased completely. The area of the mast 
cells seen in the RS was significantly larger than the one found in PS and the amount of cells 
positive of SCF had increased. SCF can serve as a growth factor for mast cells which could be 
used as an explanation as to why the remaining mast cells appeared larger than in the PS. The 
pathohistological findings in the RS revealed a clear disparity in the number of mast cells 
present in the dermis. Small groups of mast cells still dwelt in mid-dermis, but instead of 
massive aggregates in the higher dermis, slight fibrosis was found and the epidermal ridges 
were levelled out. Increased numbers of apoptotic mast cells were revealed. This suggests that 
regression of mastocytoma involves loss of proliferation and an enhanced number of 
apoptotic mast cells. Autocrine effects of SCF probably serve to promote the remaining mast 
cells in the RS (Inoue et al., 2002). 
 
The mechanisms behind spontaneous regression of infantile mastocytomas are yet to be fully 
understood. 
 
Hemangioma 
Hemangiomas of infancy 
The most frequently seen neoplasm in infants is cutaneous hemangioma. It is known to grow 
rapidly in neonates and then slowly involute. Hemangiomas are seen in 1,1-2,6 % of infants, 
at the age of one year the rate is 12%. Premature children weighing under a 1000 g have a 
22.9 % chance of getting hemangioma which suggests that placental factors might be 
involved in the pathogenesis. The tumour itself is in most cases benign and relatively 
harmless although complications often arise due to the localization (Bruckner & Frieden 
2003). 
 
The macroscopic manifestation is dependent upon which level in the dermis the hemangioma 
is to be found. Growing superficially, it normally appears as a lump of varying size, soft to 
palpate, alopecic and highly erythematous. A deeper lying tumour is naturally less noticeable 
and may just show as a raised bluish macule. Combined types also exist, with both the deep 
and superficial features (Bruckner & Frieden 2003). 
 
Involution of hemangioma 
Hemangiomas are common tumours in infants. As mentioned earlier, the hemangioma starts 
growing rapidly within a few months of birth. The peak of proliferation occurs after 9-12 
7 
months, followed by a slow involution. Generally it regresses about 10 % per year (Bruckner 
& Frieden 2003). Congenital hemangiomas are less known to undergo a proliferative phase 
and consequently seem to involute quicker (Boon et al., 1996). 
 
On microscopical examination in the proliferative phase, fat, well-differentiated, highly 
mitotic epithelial cells are organised in layers, sometimes forming lumens (Bruckner & 
Frieden 2003). During the proliferating, involuting and the completely involuted phase, the 
endothelial cells express a large variety of different growth factors. Boon et al (1996) showed 
in a study that TIMP 1, an inhibitor of neovascularisation, was expressed in the involuting 
phase together with SMC-actin, a marker of mature smooth muscle cells with inhibiting 
effects on endothelial proliferation. Furthermore, the tissue did not stain for vascular 
endothelial growth factor (VEGF) in the involuting stage. The authors suggested that 
angiogenic peptides affect proliferative cells to differentiate. The differentiated cells 
supposedly express mediators that results in the activation of mast cells and expression of 
TIMP 1. The activated mast cells are thought to produce growth factors and interferons, which 
together with TIMP 1 leads to an involution of the tumour (Boon et al., 1996). 
 
More recent findings propose that the involution of hemangioma is strongly connected to 
apoptosis, although the factor triggering the switch to regression still remains unexplored 
(Razon et al., 1998). There are also reports of an up-regulated expression of the gene coding 
for mitochondrial cytochrome b (Hasan et al., 2001)(. Modulation of the electron transport 
chain could serve as an explanation as to why the cells undergo apoptosis (Bruckner & 
Frieden 2003). 
 
The theory that presents the mast cell as the active inducer of involution is supported by a 
study where an increase in the activation of interferon-genes during the regression stage was 
shown (Ritter et al., 2002). In another study, it was found that cytoplasmatic mast cell 
granules stained for two important markers of apoptosis, Clusterin/ApoJ. Endothelial cells in 
the lesion also expressed Clusterin/ApoJ, which indicating that the mast cell forced the 
endothelial cells to undergo apoptosis (Hasan et al., 2000). 
 
 
Histiocytoma 
A histiocyte is an older name for a cell of the myeolid stem cell line; i.e. a macrophage or a 
dendritic cell. Macrophages function as sentinel cells in the immune system with the ability to 
act as a non-specific effector cells. Different lines of macrophages exist, and their names are 
dependant on location, for instance, the macrophages in the brain are called microglia, 
macrophages lining the liver endothelia are called Kuppfer cells and macrophages found in 
the lungs go by the name alveolar macrophages. Dendritic cells play a crucial part in the 
immune system, being the most important antigen presenting cells (APC). As with the 
macrophages, there are different subtypes of dendritic cells with varying denominations 
usually alongside slightly differentially expressed cell surface markers (Fulmer & Mauldin 
2007). 
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Descriptive features 
In dogs, especially those younger than three years old, cutaneous histiocytoma is a common 
neoplasm. It usually appears as a single lesion of flat or nodular character and regresses 
within 1-2 months. On microscopical evaluation, the tumour displays an infiltrative growth in 
the superficial and the deeper layer of the dermis (Fulmer & Mauldin 2007). To determine the 
origin of canine cutaneous histiocytoma (CCH), immunochemistry was performed on tumour 
tissue samples (Moore et al., 1996). The result was that the neoplastic cells in the 
histiocytoma were expressing cell surfaces markers such as CD1, CD11a, CD11c, E-cadherin 
and MHCII, some of them specific for Langerhans cells (LC), a dendritic cell seen in the 
epidermis. Additionally, some of these markers are associated with maturing LCs. When a LC 
differentiates in to a mature cell, it migrates to the paracortex in the regional lymph nodes. 
Despite this, the neoplastic LCs remained in the epidermis. It was therefore concluded that the 
CCH originates from Langerhans cells and have a tropism for the epidermis. 
 
 
Findings in the regression stage 
As previously mentioned, histiocytomas in dogs are renowned regressing tumours. The 
mechanism behind this process is thought to be regulated by the immune system. In 2006, 
Kaim et al. (2006) performed a study to elucidate the composition of cytokines and immune 
cells in histiocytomas at different stages of regression. Findings indicated an initial 
predominating abundance of CD4
+
 T-cells which later was inverted so that CD8
+
 cytotoxic T-
cells were the main cell type in the immunologic infiltrate. Furthermore, activated 
macrophages were found in the lesions. This correlated well with a significant expression of a 
number of cytokines that was also identified in the tumour; IL-2, TNF-α, IFN-γ and iNOS 
mRNA. The early infiltration of CD4
+
 T-lymphocytes was thought to be the inducing factor of 
regression, producing cytokines necessary for the following immune-response. Their release 
of IFN-γ activates macrophages, stimulates the Th1-response and enhances cytotoxic activity 
in CTLs. IL-2, produced by the T-lymphocytes, stimulates T-cell proliferation as well as 
recruits lymphokine activated killer cells (LAKs). The up-regulated expression of iNOS 
mRNA probably serves to promote the formation of nitric oxide (NO), a reactive metabolite, 
active in the intracellular lysosomes in macrophages. Based on these findings, a conclusion 
was drawn, stating that the regression of histiocytoma is dependant on a CTL-response 
initiated by activated CD4
+
 T-cells and supported by phagocytic myeloid cells. The authors 
speculated that the activation of the CD4
+
 T-lymphocytes could be induced by antigen-
presentation performed by the neoplastic Langerhans cells, thus making it a self-limiting 
neoplasm (Kaim et al., 2006). 
 
Papilloma 
Virus-induced papilloma 
Specific papillomaviruses exist for most species, generally causing benign tumours and on 
rare occasions malignant growths. The virus infects cells in the suprabasilar layer in the 
squamous epithelium. Dependant on the insertion of the viral genome, two types of papilloma 
can evolve. The cells can become hyperactive, highly mitotic and proliferative; leading to 
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hyperplasia and hyperkeratosis. The cells can also degenerate, have a nuclear located 
production of virions and eventually die. Clinical lesions are usually shown as alopecic, flat to 
papular hyperplastic formations.  A thickened stratus spinosum of the dermis is seen 
histologically, covered by a pathologically larger layer of parakeratotic or orthokeratotic 
keratin. In some papillomas, “koilocytes” are visible. This term describes swollen 
keratinocytes with a characteristic perinuclear halo and a peculiar nucleus (McGavin & 
Zachary 2007). 
 
Mechanisms of regression 
Papillomas are known to spontaneously regress. In this phase the infected cells move away 
from the peribasal layer in the epidermis, escaping possible immunologic attack since the 
higher layers receive a lesser blood supply and thus a lesser number of circulating antigen-
detecting cells (McGavin & Zachary 2007). 
 
A study made on oral keratinocytes infected with human papilloma virus (HPV) presented 
evidence that the cells underwent terminal differentiation and consequently lost their ability to 
proliferate. The cells became anucleated, squamous and more keratinized and the ratio of 
differentiated cells versus the basal-horny cells steadily increased with time. The keratinized 
cells stopped expressing proliferative cell nuclear antigen (PCNA), but expressed high levels 
of involucrin and high molecular weight keratin, both important markers of differentiation of 
keratinocytes. Eight weeks post infection, the tissue was infiltrated by immunologic cells, 
dominating the histological compound. Multinucleated foreign body type giant cells were 
disposing of keratinous debris and dystrophic microcalcifications could be seen within the 
regressing papilloma (Yoo et al., 2002). 
 
These findings suggest that the mechanisms behind regression of virus-induced papilloma are 
based on terminal differentiation of the keratinocytes, thus leading to a loss of ability to 
proliferate, followed by an immune-response from the host to discard the infected cells. 
 
DISCUSSION 
As shown above, there are still many question marks surrounding the events of natural 
regression in some tumours. For both hemangioma and mastocytoma, apoptosis seems to hold 
a key role in the involuting process, judging from the arrested proliferation and the 
dramatically increased numbers of apoptotic cells. Still, there are no obvious inducers of 
apoptosis. In hemangioma, theories suggest that the mast cell is the promoting factor of 
apoptosis (Boon et al., 1996; Hasan et al., 2000; Ritter et al., 2001). Could further 
investigation reveal a similar mechanism in the regression of mastocytoma? A possible 
explanation could be non-neoplastic mast cells forcing the monoclonal tumour cells to 
undergo self-generated cell death according to the same pattern as in the regressing 
hemangioma. 
 
In canine cutaneous histiocytoma, an inflammatory response serve as a reliable theory as to 
why the tumour undergoes involution. Theories suggest that the initiation of the regression is 
a consequence of neoplastic LCs with antigen presenting ability, activating CD4
+
 T-cells 
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which moreover promotes a CTL-mediated immune-response (Kaim et al. 2006). In the case 
of the MeLiM-pigs, tumour regression seems to be a consequence of the tumour cells being 
highly immunogenic and expressing specific tumour antigens which triggers an immune-
response (Rambow et al., 2008). Immune reactions to tumour cells is documented in other 
types of neoplasms as well and research has been done on the cytokines produced, triggering 
both cellular, mainly cytotoxic T-lymphocytes and natural killer cells (NK-cells) and humoral 
immune responses (Xiang et al., 2001) 
 
Terminal differentiation of the keratinocytes is responsible for the regression of papillomas. 
When the cell differentiates to the final stage, it loses its ability to undergo mitosis. Thus, the 
tumour progression is halted and eventually the tumour cells are exfoliated and the tumour is 
completely involuted and replaced with new non-neoplastic epidermal cells (Yoo et al., 2002). 
 
The MeLiM-pigs pathogenesis and regression of cutaneous malignant melanoma has been 
studied more in depth by performing SSH to determine changes in the gene-expression 
throughout the period of regression (Rambow et al., 2008). The results presented a clear 
overview of what genes that were up- or down-regulated compared to the proliferating phase, 
which favours the chances of discovering what factors might cause the switch. This 
information could be of the utmost value to the development of therapies designed to treat 
malignant melanoma, the most aggressive of skin cancers. 
 
All of the examples presented in the literature review are tumours of the skin. It would be 
interesting to further investigate why dermatological tumours are more likely to undergo 
spontaneous regression than other tumours, if there are features connected to the tissue itself 
that trigger the self-generated remission or if it is merely a coincidence. 
 
Hemangioma, mastocytoma, histiocytoma and the spontaneously regressing melanomas in 
Lichenov mini-pigs all undergo both a proliferative and a regression phase at a very early 
stage in life, as opposed to the most common neoplasms that occur late in life. In MeLiM-
pigs, this can be explained by the species suffering from the effects of heavy inbreeding and 
subsequently, being extremely susceptible to the development of malignant melanoma 
(Vincent-Naulleau et al., 2004). In the other cases, no confirmed theory has been presented. 
Could the early tumour development be associated with the pathogenesis of all four tumours? 
Is there possibly a connection to placental origin of the tumour tissue that triggers the 
proliferation, and is the tumour then defeated by mechanisms in the individual’s own 
immune-system? 
 
As shown above, spontaneous tumour regression can be a case of destruction by the innate 
immune response, terminal differentiation of tumour cells or increased apoptosis of tumour 
cells. It is very difficult to sum up the phenomenon of the natural occurring involution of 
tumours since the underlying mechanisms seem to alter with each tumour type. It can be 
concluded that the pathogenesis of a tumour has a crucial impact upon regression. Moreover, 
the definite trigger of the switch to regression remains unknown in most cases. More research 
needs to be done in this field to further elucidate the possible explanations as to how and why 
tumours undergo remission without external treatment. 
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